Theranos hit by another setback as it withdraws request for Zika test approval

Troubled diagnostic company Theranos suffered another blow as it withdrew its request for federal approval of a new Zika virus blood test, The Wall Street Journal reports. The Food and Drug Administration is said to have turned up evidence that Theranos began testing the diagnostic without the necessary protections for human subjects of research.
The withdrawal is just the latest in a string of setbacks
Over the past year, scandal has dogged the start-up that was once valued at $9 billion.